JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

Sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Study ID
NCT07497074
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JSKN033 — DRUG
    JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol
  • Platinum — DRUG
    JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol
  • Bevacizumab — DRUG
    JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol

Study Details

The goal of this clinical trial is to learn if the therapy of JSKN033 plus chemotherapy with or with bevacizumab is safe to treat patients with advanced cervical cancer. It will also learn about the antitumor activity and pharmacokinetic/ pharmacodynamic profiles of this therapy.

Key Dates

Start date
Apr 30, 2026
Status verified
Mar 2026
Primary completion
Oct 31, 2027
Completion
Jun 30, 2028

Study Design

Enrollment
78 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Safety run-in dose cohort 1
    JSKN033 in combination with platinum-based chemotherapy ± bevacizumab administered intravenously at dose level 1 according to protocol
  • Experimental: Safety run-in dose cohort 2
    JSKN033 in combination with platinum-based chemotherapy ± bevacizumab administered intravenously at dose level 2 according to protocol
  • Experimental: Dose expansion cohort
    JSKN033 in combination with platinum-based chemotherapy ± bevacizumab administered intravenously at a selected dose level

Primary Outcome Measure

Frequency and severity of Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: 21 days from the first dose ]

Central Contacts

Related Studies